COSMOS Pharmaceutical Corporation
3349.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥1,011,390 | ¥964,989 | ¥827,697 | ¥755,414 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Cost of Goods Sold | ¥798,109 | ¥776,683 | ¥658,979 | ¥603,966 |
| Gross Profit | ¥213,281 | ¥188,306 | ¥168,718 | ¥151,448 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥107 | ¥116 | ¥128 | ¥127 |
| SG&A Expenses | ¥152,430 | ¥138,536 | ¥122,807 | ¥107,756 |
| Sales & Mktg Exp. | ¥1,561 | ¥1,812 | ¥1,648 | ¥1,632 |
| Other Operating Expenses | ¥20,447 | ¥18,269 | ¥15,782 | ¥13,895 |
| Operating Expenses | ¥172,877 | ¥156,805 | ¥138,589 | ¥121,651 |
| Operating Income | ¥40,404 | ¥31,501 | ¥30,128 | ¥29,796 |
| % Margin | 4% | 3.3% | 3.6% | 3.9% |
| Other Income/Exp. Net | ¥1,968 | ¥2,218 | ¥2,645 | ¥3,252 |
| Pre-Tax Income | ¥42,372 | ¥33,719 | ¥32,773 | ¥33,048 |
| Tax Expense | ¥11,393 | ¥9,265 | ¥8,975 | ¥9,892 |
| Net Income | ¥30,978 | ¥24,454 | ¥23,797 | ¥23,155 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS | 390.85 | 308.61 | 300.48 | 292.37 |
| % Growth | 26.6% | 2.7% | 2.8% | – |
| EPS Diluted | 390.85 | 308.61 | 300.48 | 292.37 |
| Weighted Avg Shares Out | 79 | 79 | 79 | 79 |
| Weighted Avg Shares Out Dil | 79 | 79 | 79 | 79 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥48 | ¥44 | ¥47 | ¥52 |
| Interest Expense | ¥254 | ¥99 | ¥51 | ¥52 |
| Depreciation & Amortization | ¥22,229 | ¥19,924 | ¥17,368 | ¥15,110 |
| EBITDA | ¥64,855 | ¥53,744 | ¥50,192 | ¥48,210 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |